Close Menu

Wellcome Sanger Institute

The test for Grey Platelet Syndrome is being developed by the NHS Blood and Transplant Centre at the Addenbrooke's Biomedical campus in Cambridge, UK.

Using a so-called pairwise sequentially Markovian coalescent model, researchers from the Wellcome Trust Sanger Institute used information in individual human genomes to gain insights into human population history over hundreds of thousands of years.

Wellcome Trust Sanger Institute's COSMIC

Researchers from the Wellcome Trust Sanger Institute and elsewhere describe how they used formaldehyde-assisted isolation of regulatory elements to focus in on non-coding SNP involved in platelet function within an open chromatin region in platelet-producing megakaryocyte cells.

In Nature, researchers describe the high-throughput approach that they have used to make conditional knockouts of more than 9,000 genes in mouse embryonic stem cells.

The researchers aim to find rearrangements in the small amounts of DNA that leak out from the bone cancer into the bloodstream.

The goal of the project is two-fold: the exome sequencing portion of the study will look for genes that underlie the genesis of the disease, while whole-genome sequencing of patients' plasma will be used to look for patient-specific rearrangements that could be used as the basis for a test.

Study leader Nigel Carter said that the project will use Agilent Technologies' comparative genomic-hybridization arrays and Illumina's whole-genome SNP-genotyping arrays to gather genetic information on enrolled patients.

New Products: Mar 29, 2011

Premium

Atlas Biolabs offering Roche NimbleGen's SeqCap EZ enrichment, Sanger Institute's COSMIC 52

Pages

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.